Dermatofibrosarcoma protuberans

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 3, 2012, Pages 312-318

  Miller, Stanley J ^a   Alam, Murad ^b   Andersen, James S ^c   Berg, Daniel ^d   Bichakjian, Christopher K ^e   Bowen, Glen M ^f   Cheney, Richard T ^g   Glass, L Frank ^h   Grekin, Roy C ⁱ   Ho, Alan L ^j   Kessinger, Anne ^k   Liegeois, Nanette ^a   Lydiatt, Daniel D ^k   Michalski, Jeff ^l   Morrison, William H ^m   Nehal, Kishwer S ^j   Nelson, Kelly C ⁿ   Nghiem, Paul ^d   Olencki, Thomas ^o   Perlis, Clifford S ^p   Shaha, Ashok R ^j   Tuli, Malika ^q   Urist, Marshall M ^r   Wang, Linda C ^s   Zic, John A ^t   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l BARNES JEWISH HOSPITAL   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ DUKE CANCER INSTITUTE   (United States)

^o OHIO STATE UNIVERSITY   (United States)

^p FOX CHASE CANCER CENTER   (United States)

^q UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^t VANDERBILT INGRAM CANCER CENTER   (United States)

more..

Author keywords

Adjuvant therapy; Dermatofibrosarcoma protuberans; Imatinib; Mohs surgery; NCCN clinical practice guidelines; NCCN guidelines; Non melanoma; Radiation therapy; Sarcoma; Skin cancer

Indexed keywords

CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL PRACTICE; DERMATOFIBROSARCOMA PROTUBERANS; HUMAN; ONCOLOGY; PRACTICE GUIDELINE; REVIEW;

EID: 84863295172     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0032     Document Type: Review

References (38)

1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007;56:968-973. (Pubitemid 46720204)
2. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008;113:616-627.
3. Haycox CL, Odland PB, Olbricht SM, Casey B. Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Ann Plast Surg 1997;38:246-251. (Pubitemid 27137176)
4. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600-613. (Pubitemid 27446732)
5. Vidimos AT, Helm TN, Papay FA. Dermatofibrosarcoma protuberans. In: Cutaneous Oncology: Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Scientific; 1998:822-831.
6. Cribier B, Noacco G, Peltre B, Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 2002;46:408-413. (Pubitemid 34225406)
7. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Hum Pathol 2001;32:50-56. (Pubitemid 32150628)
8. Kim HJ, Lee JY, Kim SH, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007;157:319-324. (Pubitemid 47083868)
9. Zelger BW, Ofner D, Zelger BG. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 1995;26:519-527.
10. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998;22:576-587. (Pubitemid 28213745)
11. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-2720. (Pubitemid 30417931)
12. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000;24:1125-1130. (Pubitemid 30612834)
13. Dawes KW, Hanke CW. Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. Dermatol Surg 1996;22:530-534. (Pubitemid 26200108)
14. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;100:1008-1016. (Pubitemid 38222862)
15. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:82-87. (Pubitemid 26231329)
16. Haas AF, Sykes JM. Multispecialty approach to complex dermatofibrosarcoma protuberans of the forehead. Arch Otolaryngol Head Neck Surg 1998;124:324-327. (Pubitemid 28141733)
17. Huether MJ, Zitelli JA, Brodland DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 2001;44:656-659. (Pubitemid 32249525)
18. Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology (Williston Park) 2005;19:1165-1171; discussion 1171-1162, 1175.
19. Sondak VK, Cimmino VM, Lowe LM, et al. Dermatofibrosarcoma protuberans: what is the best surgical approach? Surg Oncol 1999;8:183-189.
20. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004;101:28-38. (Pubitemid 38812420)
21. Kimmel Z, Ratner D, Kim JY, et al. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007;14:2113-2120. (Pubitemid 46988248)
22. Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000;7:696-704.
23. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010;17:2112-2118.
24. Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 2011;18:328-336.
25. Meguerditchian AN, Wang J, Lema B, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol 2009;33:300-303.
26. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004;31:30-36. (Pubitemid 38879420)
27. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-5783. (Pubitemid 32769094)
28. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer 2004;101:2503-2508. (Pubitemid 39532278)
29. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005;16:461-466. (Pubitemid 40434613)
30. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005;23:866-873. (Pubitemid 46224187)
31. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591. (Pubitemid 34983217)
32. Ugurel S, Utikal J, Mohr P, et al. Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): a phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 9561.
33. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28:1772-1779.
34. McArthur GA. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw 2007;5:557-562. (Pubitemid 46815216)
35. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996;14:2365-2369. (Pubitemid 26264889)
36. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998;40:823-827. (Pubitemid 28150799)
37. Dagan R, Morris CG, Zlotecki RA, et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005;28:537-539. (Pubitemid 41790002)
38. Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000;57:175-181.